Form 4: Axsome Therapeutics Director Exercises Stock Options, Acquires Shares

Axsome Therapeutics director Mark Coleman exercised stock options to acquire 33,410 shares of common stock at $5.94 per share.

Summary

• On November 19, 2024, Mark Coleman, a director at Axsome Therapeutics, exercised stock options.
• This transaction involved the acquisition of 33,410 shares of common stock at a price of $5.94 per share.
• Following the transaction, Mr. Coleman directly owns 48,010 shares and indirectly owns 403,856 shares.
• The indirectly held shares are owned through an entity where Mr. Coleman has voting and dispositive power.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a routine stock option exercise. It does not indicate any positive or negative sentiment.

Positives

• The exercise of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option exercises are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The transaction is consistent with standard practices for insider trading and reporting requirements.
• Similar transactions are regularly reported by directors and officers of comparable companies such as Biohaven, Sage Therapeutics, and Neurocrine Biosciences.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Axsome Therapeutics, AXSM, director, equity